ABCELLERA BIOLOGICS INC (ABCL) Stock Income Statement
NASDAQ:ABCL - Nasdaq - CA00288U1066 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.11M | 28.83M | 38.02M | 485.40M | 375.20M | |||
| Operating Expenses | 345.65M | 343.60M | 275.23M | 268.90M | 170.80M | |||
| Research and Development | 170.47M | 167.26M | 175.66M | 107.90M | 62.10M | |||
| Selling, General, and Administrative Expenses | 83.84M | 85.49M | 75.18M | 66.80M | 48.80M | |||
| Operating Income | -322.53M | -314.77M | -237.21M | 216.50M | 204.40M | |||
| Interest Income/Expense | 53.52M | 55.87M | 46.15M | 12.00M | -2.80M | |||
| Other Income/Expense | 58.38M | 58.50M | 17.03M | 10.60M | 17.50M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -210.63M | -200.40M | -174.03M | 239.10M | 219.10M | |||
| Income Tax | -42.76M | -37.54M | -27.63M | 80.60M | 65.70M | |||
| Net Income | -167.87M | -162.86M | -146.40M | 158.50M | 153.50M | |||
| EBITDA | -229.92M | -223.92M | -212.81M | 244.40M | 218.90M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.57 | -0.55 | -0.51 | 0.50 | 0.48 | |||
| Non GAAP EPS | -0.56 | -0.55 | -0.52 | 0.50 | 0.47 | |||
| Statistics | ||||||||
| Profit Margin | -726.23% | -564.83% | -385.00% | 32.65% | 40.91% | |||
| Operating Profit Margin | -1395.34% | -1091.69% | -623.82% | 44.60% | 54.48% | |||
All data in USD